Outputs (4)

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects (2019)
Journal Article
Al-Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R., & Madden, L. A. (2019). The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, https://doi.org/10.1007/s12020-019-02059-9

© 2019, The Author(s). Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals... Read More about The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects.

The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome (2019)
Journal Article
Sathyapalan, T., Hobkirk, J. P., Javed, Z., Carroll, S., Coady, A. M., Pemberton, P., Smith, A., Cianflone, K., & Atkin, S. L. (2019). The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in endocrinology, 10(JUN), Article 394. https://doi.org/10.3389/fendo.2019.00394

Copyright © 2019 Sathyapalan, Hobkirk, Javed, Carroll, Coady, Pemberton, Smith, Cianflone and Atkin. Background: Atorvastatin has been shown to improve cardiovascular risk (CVR) indices in women with polycystic ovary syndrome (PCOS). Low-grade chroni... Read More about The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More about Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.

A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E., Mann, V., Corless, L., Abouda, G., Rigby, A. S., Atkin, S., & Sathyapalan, T. (2019). A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1), 188. https://doi.org/10.3390/nu11010188

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemis... Read More about A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome.